Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hallvard Holdaas

Showing results (11-20 of 156) with videos related to

Pageof 16
Sort By:
Evidence-Based Cardiovascular Medicine|March 15, 2006
Fluvastatin may be similarly effective in older and younger peopleHallvard Holdaas, Debbie Singh
Kidney International|August 1, 2014
The authors replyGeir Mjøen, Hallvard Holdaas
The New England Journal of Medicine|May 26, 2016
Kidney-Failure Risk Projection for the Living Kidney-Donor CandidateGeir Mjøen, Hallvard Holdaas
Transplant International : Official Journal of the European Society for Organ Transplantation|November 14, 2015
Regarding long-term outcome after kidney donationGeir Mjøen, Hallvard Holdaas
Renal Failure|June 17, 2005
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantationAlberto Corsini, Hallvard Holdaas
Annals of Internal Medicine|August 22, 2018
Mid- and Long-Term Health Risks in Living Kidney DonorsGeir Mjoen, Hallvard Holdaas
Journal of the American Society of Nephrology : JASN|March 15, 2014
BP targets in renal transplant recipients: too high or too low?Hallvard Holdaas, Alan G Jardine
Journal of the American Society of Nephrology : JASN|November 16, 2013
Functional cardiopulmonary exercise testing in potential renal transplant recipientsBengt Fellstrom, Hallvard Holdaas, Alan Jardine
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 27, 2012
Diabetes, chronic kidney disease and cancer riskAnders Hartmann, Trond Jenssen, Hallvard Holdaas
Kidney International|May 3, 2014
The authors reply:Geir Mjøen, Stein Hallan, Hallvard Holdaas
Pageof 16

Showing results (11-20 of 156) with videos related to

Sort By:
Pageof 16
Evidence-Based Cardiovascular Medicine|March 15, 2006
Fluvastatin may be similarly effective in older and younger peopleHallvard Holdaas, Debbie Singh
Kidney International|August 1, 2014
The authors replyGeir Mjøen, Hallvard Holdaas
The New England Journal of Medicine|May 26, 2016
Kidney-Failure Risk Projection for the Living Kidney-Donor CandidateGeir Mjøen, Hallvard Holdaas
Transplant International : Official Journal of the European Society for Organ Transplantation|November 14, 2015
Regarding long-term outcome after kidney donationGeir Mjøen, Hallvard Holdaas
Renal Failure|June 17, 2005
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantationAlberto Corsini, Hallvard Holdaas
Annals of Internal Medicine|August 22, 2018
Mid- and Long-Term Health Risks in Living Kidney DonorsGeir Mjoen, Hallvard Holdaas
Journal of the American Society of Nephrology : JASN|March 15, 2014
BP targets in renal transplant recipients: too high or too low?Hallvard Holdaas, Alan G Jardine
Journal of the American Society of Nephrology : JASN|November 16, 2013
Functional cardiopulmonary exercise testing in potential renal transplant recipientsBengt Fellstrom, Hallvard Holdaas, Alan Jardine
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 27, 2012
Diabetes, chronic kidney disease and cancer riskAnders Hartmann, Trond Jenssen, Hallvard Holdaas
Kidney International|May 3, 2014
The authors reply:Geir Mjøen, Stein Hallan, Hallvard Holdaas
Pageof 16